Clear-Cell RCC: First Molecular Prognostic Marker for Drug Targeting

Share this content:

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific survival and tumor recurrence. Dr. Ari Hakimi MD, from Memorial Sloan-Kettering Cancer Center in New York gave the 2014 ASCO Genitourinary Cancers Symposium his group's findings about the MET oncogene variant which they found to be associated with poor outcomes. He noted that the mechanism made clear by this research could provide a basis for drug targeting in the future while already providing doctors with their first clinically useful molecular biomarker.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs